39 results about "Skeletal muscle cell" patented technology

The invention provides screening and analysis of LncRNA related to skeletal muscle development in the muscle development process of Tan sheep in a salt pond, and particularly relates to application of Lnc.23721 and a target gene CDKN1A thereof in regulation and control of skeletal muscle development of Tan sheep, and the sequence of the CDKN1A gene is as shown in SEQ ID NO.1. The invention further provides application of the Lnc.23721 and the target gene CDKN1A in regulation and control of skeletal muscle development of Tan sheep in the salt pond Tan sheep. Specifically, the expression level of the CDKN1A is up-regulated, the differentiation of the skeletal muscle cells and myotube formation of the Tan sheep can be inhibited, the expression level of the CDKN1A is down-regulated, and the myogenic differentiation and slow muscle fiber formation of the skeletal muscle cells of the Tan sheep can be promoted, so that the meat production performance of the Tan sheep can be improved, and the formation of tender meat is facilitated. The invention also provides the LncRNA capable of regulating and controlling the development of the skeletal muscle of the Tan sheep, and the nucleotide sequence of the LncRNA Lnc.23721 is as shown in SEQ ID NO. 2. Specifically, by down-regulating the expression level of Lnc.23721, the differentiation of the Tan sheep skeletal muscle cells can be inhibited.

The invention discloses a metabolite for treating sarcopenia and application of the metabolite in a health-care product additive, and belongs to the technical field of biomedicine, and the application comprises application of indole-3-formaldehyde in preparation of a medicine for treating sarcopenia. The invention further discloses a health care product additive and a medicine for treating sarcopenia, wherein the medicine comprises indole-3-formaldehyde. According to the present invention, the indole-3-formaldehyde can be adopted as the health product additive or the effective component in the drug, can be used for treating sarcopenia, and can recover the skeletal muscle cell mitochondrial homeostasis so as to improve the muscle cell mitochondrial function index.

Myotonic Dystrophy type 1 (DM1) is an inherited disease characterized by multi-systemic symptoms, particularly in skeletal muscles (progressive weakness and atrophy, myotonia). The inventors screened 7 500 bioactive compounds for their ability to improve the myogenic fusion and reduce the molecular hallmarks of DM1 skeletal muscle cells. The inventors found that five compounds, all inhibiting HDAC6, a cytoplasmic histone deacetylase, were effective at the micromolar range in normalizing the myogenic fusion, reducing the number of nuclear foci of mutant DMPK mRNA, decreasing the expression level of DMPK mRNA, restoring the splicing of several genes, and increasing the acetylation of SMAD3, a transcription factor involved in muscle development. The effects of HDAC6 inhibitors were observed both in immortalized and hiPSC-derived skeletal muscle cells from DM1 patients, and in different stages of differentiation. Thus, the present invention relates to the use of selective HDAC6 inhibitors for the treatment of DM1.

The application discloses a milk-derived polypeptide VSL for promoting proliferation of skeletal muscle cells and application thereof, and belongs to the field of bioactive peptides. The milk-derived bioactive polypeptide VSL has the effect of promoting proliferation of muscle cells, and is expected to be used for preparing drugs for promoting proliferation of muscle cells and preventing sarcopenia. The milk-derived bioactive polypeptide VSL is convenient to synthesize, can be produced industrially, and has a good application prospect in the fields of food, medicine and cosmetics.

Provided herein are compositions comprising a muscle (cardiac and / or skeletal) cell targeting peptide linked to or inserted into a targeting protein of a recombinant vector having at least one exogenous peptide comprising Xn-RGD-n-mer-Xm. Compositions providing such conjugates, targeting peptides, or recombinant vectors with engineered capsid or envelope proteins are provided, along with uses thereof.

The invention discloses a compound enzyme preparation-containing nutritional feed for regulating and controlling intramuscular fat of black pigs and a preparation method of the compound enzyme preparation-containing nutritional feed, and relates to the technical field of livestock and poultry breeding feeds. The invention discloses a black pig skeletal muscle cell fat directional transport feed which is prepared from the following components in parts by weight: 850-920 parts of basal feed, 5-12 parts of fat directional deposition compound enzyme group, 25-40 parts of amino acid-enzymatic synthesis substrate combination and 2-6 parts of lipolytic enzyme specific inhibitor. According to the black pig skeletal muscle cell fat directional transport feed, fat precursor directional transport is realized through the compounded fat directional deposition compound enzyme group, a fat synthesis pathway targeting black pig skeletal muscle cells and lipoprotein lipase; acetyl-coenzyme A carboxylase and fatty acid synthetase catalyze fat synthesis step by step, only intramuscular fat generation pathways are activated, subcutaneous and abdominal fat deposition paths are blocked, the technical defects that fat deposition of an existing single enzyme preparation is non-directional, and the body fat rate is caused to be abnormally increased are overcome, meanwhile, an exclusive amino acid-enzymatic synthesis substrate combination is matched, and the body fat synthesis efficiency is improved. Sufficient adaptive substrates are supplied to enzyme group catalytic reaction, and the problem that a single enzyme preparation is insufficient in catalytic efficiency is solved.

To provide methods for producing an artificial skeletal muscle tissue from pluripotent stem cells.SOLUTION: The present invention describes a method for preparing an engineered skeletal muscle tissue, as well as skeletal myoblasts, skeletal myotubes, and satellite cells, a medium used being serum-free and different chemicals and their concentrations, as well as the physical stimuli, being defined. Additionally, the methods described herein are performed without transfection of human cells with transgenes. The engineered skeletal muscle cells exhibit myoblast-, myotube-, or satellite cell-specific genetic markers, demonstrating efficient differentiation of these cell types. Despite its engineered production, the skeletal muscle tissue possesses excellent stimulus-dependent contractility and exhibits contractions in response to different stimulation frequencies.SELECTED DRAWING: None

RNAi agents, compositions comprising RNAi agents, and methods for inhibiting the DM1 protein kinase (DMPK) gene are described. The DMPK RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of the DMPK gene. Pharmaceutical compositions comprising one or more DMPK RNAi agents, optionally together with one or more additional therapeutic agents, are also described. Delivery of the described DMPK RNAi agents to skeletal muscle cells in vivo results in the inhibition of DMPK gene expression and a reduction in DMPK protein levels, more specifically, a reduction in mutant DMPK-CUG protein levels, which can provide therapeutic benefits to subjects, including human subjects suffering from certain skeletal muscle-related diseases or disorders, including myotonic dystrophy type 1.

The invention relates to application of an FGFBP2 gene in regulation and control of growth and development and cell cycle of chicken skeletal muscle. The inventor finds the existence of the FGFBP2 gene in early-stage work of a team, and also finds that the expression quantity difference of the gene in muscular tissues of chickens in different development stages and varieties is obvious. In order to further reveal the effect of the FGFBP2 gene in the growth and development process of chicken skeletal muscles, the FGFBP2 gene is overexpressed in chicken myoblasts and AA broiler chickens respectively by using an overexpression technology, and detection finds that the overexpressed FGFBP2 gene can promote the proliferation of myoblasts. The discovery that the FGFBP2 gene can regulate and control the proliferation function of the chicken skeletal muscle cells provides a new theoretical basis for revealing the development of the chicken skeletal muscle and improving the meat production character, and provides a new thought for improving the meat production performance of livestock.

The present invention relates to a composition comprising sialyloligosaccharide and N-acetylmannosamine for the treatment of GNE myopathy, and a method of using same. Despite ManNac exhibiting non-significant sialylation activity in GNE knockdown (GNE KD) C2C12 skeletal muscle cells, it was confirmed that co-administration of ManNac and sialyloligosaccharide promotes sialylation more effectively than single administration, thereby exhibiting an excellent synergistic effect. Such effects have also been confirmed in an animal model of GNE myopathy, and thus the combined therapy of ManNAc and sialyloligosaccharide of the present invention is expected to be advantageously employed as a novel therapeutic approach capable of overcoming hyposialylation caused by sialic acid deficiency in GNE myopathy.

The invention relates to the technical field of bioinformatics, and discloses a three-dimensional virtual myocardial cell reconstruction method, system, equipment and medium based on cell membrane boundary division, a multi-feature joint matching strategy is adopted, the cross-layer cell tracking accuracy is greatly improved, and the problem of trajectory breakage caused by large volume and multi-core characteristics of myocardial cells is solved; secondly, the data processing efficiency is remarkably improved through an automatic feature extraction model; moreover, three-dimensional integration of space transcriptome data and cell morphological characteristics is innovatively realized, an adult myocardial cell three-dimensional model containing gene expression information is constructed on a single cell level for the first time, and unprecedented spatial resolution is provided for researching a molecular mechanism of heart diseases. The method is suitable for myocardial cell research, the technical framework of the method can be expanded to three-dimensional reconstruction of other large-volume cells such as skeletal muscle cells, neurons and hepatocytes, and the method has wide scientific research and clinical application value.

The application discloses a use and application based on CDKN1A influence on proliferation and differentiation of goat skeletal muscle, relates to the field of agricultural genetic engineering, and discloses that iRNA-seq and RNA-seq technology reveals mRNA expression maps of the longest dorsal muscle of 5-month-old Hainan black goats and 24-month-old Hainan black goats in two development stages, and CDKN1A with differential expression is screened out; the CDKN1A gene is used for negatively regulating proliferation of goat myoblasts; and the application finds that CDKN1A has a regulation effect on proliferation and differentiation of skeletal muscle cells of Hainan black goats, and can be applied to development and utilization of germplasm resources of the breed and seed selection and breeding.

This invention relates to an immortalized chicken skeletal muscle satellite cell line, its construction method, and its applications, belonging to the field of biotechnology. The immortalized chicken skeletal muscle satellite cell line Im MSLC of this invention, with accession number CCTCC NO: C2023115, was deposited on July 5, 2023, at the China Center for Type Culture Collection, located at No. 299 Bayi Road, Wuchang District, Wuhan City, Hubei Province, Wuhan University. The immortalized chicken skeletal muscle satellite cell line of this invention maintains a similar growth rate and consistent growth trend to primary chicken skeletal muscle cells after 10 passages, and retains the same cell morphology as primary cells after 22 passages; moreover, the immortalized chicken skeletal muscle satellite cell line still possesses differentiation ability after 10 passages. The immortalized chicken skeletal muscle satellite cell line provided by this invention reduces the use of chicken embryos and lowers the possibility of difficulty in obtaining stable and reliable results due to different batches of chicken embryos from which skeletal muscle cells are derived.

The present application discloses the use of SUR2 receptor modulators. In the present application, SUR2 receptor modulators (e.g. MLC1) can be combined with skeletal muscle cell K ATP SUR2 specific binding on potassium ion channel, thus enhancing intracellular calcium signal, increasing glucose uptake of skeletal muscle cell and reducing blood glucose, and thus can be used as a therapeutic drug for diabetes; SUR2 receptor modulators selectively bind to SUR2 through a non-islet β cell dependent mechanism, and have no inhibitory effect on islet β cell SUR1 receptor, and thus can effectively avoid hypoglycemia while reducing blood glucose, and have small side effects.

This invention relates to the application of *Hirudo medicinalis* in the preparation of drugs that promote skeletal muscle cell differentiation and / or prevent muscle atrophy, belonging to the field of biomedical technology. The skeletal muscle cells are myoblasts. In vitro, this drug can promote differentiation by upregulating the expression of myosin heavy chain (MyHC), myogenin, and myogenic determinant MyoD, thereby increasing myotube diameter. In vivo, it can improve doxorubicin-induced skeletal muscle atrophy in mice and repair muscle fiber damage caused by natural aging nematodes. The chemotherapeutic drug is doxorubicin, which can exert an anti-atrophy effect by maintaining the expression of myosin heavy chain (MyHC) and improving myotube morphology damage. This invention is the first to discover and experimentally demonstrate that *Hirudo medicinalis* freeze-dried powder has the activity of promoting myoblast differentiation and preventing muscle atrophy, opening up new applications for traditional Chinese medicine leeches in the prevention and treatment of muscle atrophy and expanding the medicinal value of *Hirudo medicinalis*.

The invention discloses a traditional Chinese medicine composition for enhancing functions of mature skeletal muscle cells and application of the traditional Chinese medicine composition. The composition is prepared from ginseng, astragalus membranaceus, pericarpium citri reticulatae, dogwood and rhizoma polygonati according to a specific ratio. The invention also provides an establishment method based on the quality standard of various active components (ginsenoside Rg1, hesperidin and the like) in the composition. The traditional Chinese medicine composition disclosed by the invention does not have a remarkable activity promoting effect on undifferentiated C2C12 myoblasts in a proliferation period, but can specifically enhance the cell activity of differentiated mature C2C12 myotubular cells. The action characteristics of the cell state dependence show that the composition does not simply stimulate cell proliferation, but is targeted to improve the functional state of mature muscle cells, so that a high-precision solution is provided for treating diseases (such as sarcopenia) characterized by mature muscle fiber function decline.

The invention belongs to the technical field of cell culture, and relates to a low-serum culture medium for maintaining cell proliferation and improving transfection efficiency and a culture method. It is found for the first time that culture conditions are accurately regulated and controlled by providing a stable micromolecule component combination, and the method can be used for proliferation culture of various human and animal cells; the addition of serum in the original proliferation culture medium is reduced, the proliferation effect similar to that of the original culture medium is achieved, and the subsequent differentiation of cells is not influenced; experiments prove that the culture medium and the culture method have the advantages that the addition amount of serum in the culture process of porcine skeletal muscle satellite cells, mouse myoblasts, porcine kidney fibroblasts and mouse skeletal muscle cells is reduced, the biosafety risk in the experiment is reduced, the repeatability and reliability of the experiment are improved, the cost is saved, and the culture medium and the culture method are suitable for large-scale popularization and application. And a solid foundation is provided for subsequent exploration of a normal and efficient cell culture technology under a serum-free condition.

The invention discloses an application of mouse muscle cell-derived apoptosis vesicles in muscle physiological regulation, the vesicles are apoptosis vesicles generated in a myogenic differentiation process, are derived from a normal physiological state and are not generated by chemical drug induction, and vesicle content abnormity caused by damage of a cell homeostasis under drug stimulation is avoided; experimental data shows. The apoptosis vesicles can promote differentiation and development of skeletal muscle cells in vivo and in vitro, remarkably delay muscle atrophy caused by aging or diabetes, and contribute to research and development of skeletal muscle disease related drugs.

The invention discloses a medicinal and edible composition for improving muscle attenuation of old people, the composition comprises fructus piperis longi and radix asparagi extracts, and the composition is combined with highland barley, common turnip, maca, D-psicose and other active substances to develop a series of medicinal and edible compositions for improving muscle attenuation. The composition disclosed by the invention has a good protective effect in improvement of old-age muscle attenuation, and can be applied to muscle attenuation and exercise ability decline accompanied by aging, so that the activity of telomerase is enhanced; meanwhile, the traditional Chinese medicine composition is helpful for adjusting the proportion of immune cell subtypes, improving functional activity decline of an immune system and reducing chronic low-level inflammation states, and has both safety and effectiveness. Molecular mechanism research shows that the compound activates glutathione metabolism and inhibits ferroptosis signals to reverse skeletal muscle cell senescence. The composition disclosed by the invention can be developed into foods and health-care products for improving muscle mass, volume, strength and functions, and has a very good application prospect.

The invention relates to a micropterus salmoides skeletal muscle cell line and an establishment method thereof, and belongs to the technical field of aquatic organism cells. At present, research on molecular metabolism pathways of fish for regulating and controlling muscle quality is less due to large individual difference of fish, the method for continuously and efficiently culturing the micropterus salmoides cell line comprises the following steps: treating dorsal muscle tissues of micropterus salmoides, sequentially flushing, digesting, stopping digesting and cleaning, and culturing the micropterus salmoides cell line in a culture medium to obtain the micropterus salmoides cell line. Pasting the tissue block into a T25-coated cell culture bottle for standing, adding a complete culture medium to start primary culture, observing the cell emigration condition at the edge of the tissue block, carrying out subculture by using a pancreatin digestion method containing EDTA when the emigrated cells are fused and spread at the bottom of the bottle, and replacing a subculture medium after the subculture exceeds 15 generations, and cryopreserving the cells which are good and stable in culture state for later use, and resuscitating the cells when the cells are used. According to the method, the cell migration efficiency is greatly improved, and a new path is opened up for continuously culturing the skeletal muscle cell line of the micropterus salmoides.

RNAi agents, compositions comprising RNAi agents, and methods for inhibiting the DM1 protein kinase (DMPK) gene are described herein. The DMPK RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of the DMPK gene. Also described are pharmaceutical compositions comprising one or more DMPK RNAi agents, optionally with one or more additional therapeutic agents. Delivery of the DMPK RNAi agents in vivo to skeletal muscle cells provides inhibition of DMPK gene expression and reduction of DMPK protein levels, and more particularly provides reduction of mutant DMPK-CUG protein levels, which can provide therapeutic benefits to subjects suffering from certain skeletal muscle related diseases or disorders, including type 1 ankylosing muscular dystrophy, including human subjects.

The invention discloses application of a nuclear receptor FXR in regulation and control of skeletal muscle growth and development and muscle fiber type conversion, and belongs to the field of molecular biology. Animal experiments confirm that compared with wild mice, growth and development of skeletal muscles of FXR knockout mice are inhibited, the content of glycolytic muscle fibers in the skeletal muscles is increased, and regeneration and repair of the skeletal muscles after injury are inhibited; through administration of a cell FXR agonist GW4064, it is found that activation of FXR can promote growth and development of skeletal muscle cells and differentiation of myoblasts, and the results show that the nuclear receptor FXR can positively regulate and control growth and development as well as regeneration and repair of skeletal muscles. The invention provides a new target basis for research and development of drugs for treating skeletal muscle diseases and meat product optimization in animal husbandry production, and has outstanding economic significance and wide application prospects.

The present invention relates to a pluripotent stem cell comprising an expression construct for expressing an MYOD protein and an expression construct for expressing an MYOG # protein. The invention further provides methods comprising the production of skeletal muscle cells using pluripotent stem cells and foods comprising skeletal muscle cells or pluripotent stem cells.

The invention discloses a specific skeletal muscle cell targeting liposome and a preparation method thereof, and belongs to the technical field of skeletal muscle tissue targeting. The lipidosome specifically targeting the skeletal muscle cells comprises a lipidosome body, and the surface of the lipidosome body is modified with a peptide fragment specifically bound by polyethylene glycol-amino acid containing an acidic side chain and biotin-streptavidin-laminin. The lipidosome for specifically targeting the skeletal muscle cells can be enriched at skeletal muscle tissues, and the coated recombinant adeno-associated virus can be efficiently released around the skeletal muscle cells.

The invention relates to the technical field of cell engineering, and discloses a chronic heat stress model construction method based on chick embryo primary skeletal muscle cells, which comprises the following steps: step 1, separating and purifying cells, and recording as P0 generation; step 2, differentiating after the cells are subcultured to a P2 generation; step 3, constructing a chronic heat stress model: continuously treating the differentiated cells in an incubator at 43 DEG C for 24 hours; 4, model verification, wherein the effectiveness of the model is confirmed by detecting at least one index of lactic dehydrogenase activity, cell apoptosis rate, ROS level, oxidation reduction state and HSP70 / Caspase-3 gene expression quantity. According to the method, a chronic heat stress model based on chick embryo primary skeletal muscle cells is established, and the in-vitro simulation of the chronic heat stress state of the broiler chicken is realized through standardized cell separation, passage differentiation and continuous 24-hour treatment at 43 DEG C.

The invention provides a preparation method of rice bran protein carnosine, and belongs to the technical field of food. The preparation method comprises the following steps: uniformly mixing rice bran protein and alkaline protease in water, and performing enzymolysis to obtain hydrolysate; carrying out ultrafiltration separation on the hydrolysate to obtain a C4 component; carrying out ion exchange chromatography separation on the C4 component to obtain two rice bran protein carnopotropic peptides, namely F1 and F2 respectively; the mass concentration of the rice bran protein in water is 2-4%; the addition amount of the alkaline protease in the water is 3500-4500 U / g; the molecular weight interval of ultrafiltration separation is lt; 1 KDa. The preparation method disclosed by the invention is simple in step and efficient, has high free radical scavenging capacity, and can relieve skeletal muscle cell atrophy induced by inflammation and muscle differentiation abnormity caused by inflammation so as to resist muscle injury.

The present invention relates to a pluripotent stem cell comprising an expression construct for expressing an MYOD protein and an expression construct for expressing a PAX7 protein. The invention further provides methods comprising the production of skeletal muscle cells using pluripotent stem cells and foods comprising skeletal muscle cells or pluripotent stem cells.

The application relates to application of a recombinant protein to preparation of a medicine for inhibiting muscle atrophy, and belongs to the field of biological medicines. The application discloses application of a recombinant protein AGGF1 to preparation of a medicine for inhibiting muscle atrophy. The recombinant AGGF1 protein can inhibit mouse muscle atrophy (peripheral nerve injury muscle atrophy and cachexia muscle atrophy) and loss of skeletal muscle cell protein content. Therefore, the recombinant AGGF1 protein can be used for preparation of an anti-muscle atrophy medicine and treatment of muscle atrophy caused by lumbar intervertebral disc herniation and cachexia.

The present invention relates to the provision of a recombinant adeno-associated virus (rAAV)-based delivery vector comprising an oligopeptide insert having a length of at least 5 amino acids, which shows enhanced transduction efficiency in one or more muscle cells, in particular in cardiomyocytes and / or skeletal muscle cells. The rAAV vectors of the present disclosure are useful in the treatment and / or prevention of heart-related and / or muscle-related diseases or disorders and / or in gene therapy. The invention also provides methods of treating heart-related and / or muscle-related diseases or conditions.

The invention discloses a natural compound for inhibiting disulfide death by taking VAV3 as a target spot and application of the natural compound. Belongs to the technical field of biological medicine and pharmacy. According to the invention, through virtual screening and surface plasmon resonance technologies, seven small molecular compounds, including kaempferol, liensinine, sophocarpidine, isorhamnetin, deoxyshikonin, harmine and potenoside, which can be specifically bound with VAV3 protein are screened from a natural product library for the first time. In a C2C12 cell insulin resistance model, the compounds can significantly reduce the cell death rate caused by disulfide death, and the action mechanism of the compounds is to improve the activity or expression of VAV3, inhibit abnormal accumulation of cystine and improve the NADPH level, thereby effectively preventing disulfide bond crosslinking and collapse of an actin filament network. Experiments show that the compound provided by the invention can effectively inhibit disulfide death of skeletal muscle cells by targeting VAV3, and a new lead compound and a solution are provided for developing drugs for treating diabetic muscle dysfunction and related metabolic diseases.